2022
Efficacy and Safety of Intravenous Golimumab in Patients With Ankylosing Spondylitis and Complete Spinal Ankylosis
Deodhar A, Chakravarty SD, Shiff NJ, Lo KH, Xu S, Hsia EC, Danve A, Reveille JD. Efficacy and Safety of Intravenous Golimumab in Patients With Ankylosing Spondylitis and Complete Spinal Ankylosis. JCR Journal Of Clinical Rheumatology 2022, 28: 420-423. PMID: 35649533, PMCID: PMC9704810, DOI: 10.1097/rhu.0000000000001857.Peer-Reviewed Original ResearchMeSH KeywordsAdministration, IntravenousAnkylosisAntibodies, MonoclonalAntirheumatic AgentsHumansSpondylitis, AnkylosingTreatment Outcome
2020
The effect of intravenous golimumab on health-related quality of life and work productivity in adult patients with active ankylosing spondylitis: results of the phase 3 GO-ALIVE trial
Reveille JD, Hwang MC, Danve A, Kafka S, Peterson S, Lo KH, Kim L, Hsia EC, Chan EKH, Deodhar A. The effect of intravenous golimumab on health-related quality of life and work productivity in adult patients with active ankylosing spondylitis: results of the phase 3 GO-ALIVE trial. Clinical Rheumatology 2020, 40: 1331-1341. PMID: 32926247, DOI: 10.1007/s10067-020-05342-7.Peer-Reviewed Original ResearchMeSH KeywordsAdultAntibodies, MonoclonalAntirheumatic AgentsDouble-Blind MethodHumansQuality of LifeSeverity of Illness IndexSpondylitis, AnkylosingTreatment OutcomeConceptsHealth-related qualityDisease activityWeek 52Work Limitations QuestionnaireIntravenous golimumabWeeks 0Week 16Functioning outcomesEQ-5D-5L indexPlacebo-crossover groupProductivity loss scoresEffective treatment optionVisual analog scaleConclusionsIn patientsPlacebo groupSpondylitis QualityAdult patientsAnalog scaleEQ-VASWeek 28Treatment optionsProductivity outcomesWeek 8GolimumabHRQoL